Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
Brief Overview of The Trianni Mouse Platform
Sponsored PublicationsTRIANNI’s antibody discovery platform, The Trianni Mouse, represents best-in-class technology for efficient generation of fully-human monoclonal antibodies.
Investors keen to put money into AMR SMEs
Latest NewsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
Santhera’s idebenone not efficient in PPMS patients
Latest NewsSwiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
Radek píek to become new CEO of SOTIO
AppointmentsSOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek píek as Chief Executive Officer.
Inhaled IL-4 halts neuron destruction in MS models
Latest NewsAn US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system.
Mission Therapeutics promotes Paul Thompson to VP
AppointmentsToday Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
Convert Pharmaceuticals SA closes €13.6m Series A round
Latest NewsLiège-based Convert Pharmaceuticals SA has been granted a total of €13.6m in equity and non-dilutive funding by investors Droia Oncology Ventures, Meusinvest and Spinventure, with non-dilutive support by the Walloon region and funds from the European Eurostars programme.
Rentschler Biopharma appoints Federico Pollano as Senior VP of Business Development
AppointmentsRentschler Biopharma SE, a service provider for biopharmaceuticals, today announced the appointment of Mr. Federico Pollano as the new Senior Vice President of Business Development, effective March 1.
Novo Holdings launches €135m fund to combat antimicrobial resistance
Latest NewsEU-Commission appoints Jean-Eric Paquet
AppointmentsPaquet is a French national who since November 2015 has served as one of the three Deputy Secretaries-General of the Juncker Commission, and has now been been appointed as Director General of DG Research and Innovation